New class of orthopoxvirus antiviral drugs that block viral maturation

Journal of Virology

Volumn 78, Issue 22, 2004, Pages 12147-12156

  Byrd, Chelsea M ^a   Bolken, Tove C ^b   Mjalli, Adnan M ^c   Arimilli, Murty N ^c   Andrews, Robert C ^c   Rothlein, Robert ^c   Andrea, Tariq ^c   Rao, Mohan ^c   Owens, Katrina L ^b   Hruby, Dennis E ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b SIGA Technologies Incorporated   (United States)

^c TransTech Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYSTEINE PROTEINASE; PROTEIN 17L; TTP 123045; TTP 130961; TTP 174878; TTP 176510; TTP 200480; TTP 201018; TTP 6171; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS; ANTIBIOTIC RESISTANCE; ARTICLE; BIOINFORMATICS; CELL LINE; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; ELECTRON MICROSCOPY; ENCEPHALOMYOCARDITIS VIRUS; ENZYME BINDING; GENETIC RESISTANCE; HUMAN; HUMAN CELL; IC 50; MOLECULAR MODEL; NONHUMAN; OPEN READING FRAME; ORTHOPOXVIRUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROCESSING; PSEUDOMONAS AERUGINOSA; SACCHAROMYCES CEREVISIAE; TISSUE CULTURE; VACCINIA VIRUS; VIROGENESIS; VIRUS GENE; VIRUS INDUCTION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS MORPHOGENESIS; VIRUS MUTANT; WILD TYPE;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HELA CELLS; HUMANS; MOLECULAR SEQUENCE DATA; ORTHOPOXVIRUS; VIRUS REPLICATION;

EID: 7644238046     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.22.12147-12156.2004     Document Type: Article

References (25)

1. Andres, G., A. Alejo, C. Simon-Mateo, and M. L. Salas. 2001. African swine fever virus protease, a new viral member of the SUMO-1 specific protease family. J. Biol. Chem. 276:780-787.
2. Berger, N. A., G. Weber, A. S. Kaichi, and S. J. Petzold. 1978. Relation of poly(adenosine dipohosporibose) synthesis to DNA synthesis and cell growth. Biochim. Biophys. Acta 519:105-117.
3. Blasco, R., and B. Moss. 1995. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158:157-162.
4. Byrd, C. M., T. C. Bolken, and D. E. Hruby. 2002. The vaccinia virus I7L gene product is the core protein proteinase. J. Virol. 76:8973-8976.
5. Byrd, C. M., T. C. Bolken, and D. E. Hruby. 2003. Molecular dissection of the vaccinia virus I7L core protein proteinase. J. Virol. 77:11279-11283.
6. Condit, R. C., A. Motyczka, and G. Spizz. 1983. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology 128:429-443.
7. Cundy, K. C. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36:127-143.
8. Daddow, L. Y. 1986. An abbreviated method of the double lead stain technique. J. Submicrosc. Cytol. 18:221-224.
9. De Clercq, E. 2002. Cidofovir in the treatment of poxvirus infections. Antivir. Res. 55:1-13.
10. Fulginiti, V. A., A. Papier, J. M. Lane, J. M. Neff, and D. A. Henderson. 2003. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis. 37:251-271.
11. Heller, E., M. Argaman, H. Levy, and N. Goldblum. 1969. Selective inhibition of vaccinia virus by the antibiotic rifampicin. Nature 222:273-274.
12. Herrmann E. C., Jr. 1968. Sensitivity of herpes simplex virus, vaccinia virus, and adenoviruses to deoxyribonucleic acid inhibitors and thiosemicarbazones in a plaque suppression test. Appl. Microbiol. 16:1151-1155.
13. Hruby, D. E., L. A. Guarino, and J. R. Kates. 1979. Vaccinia virus replication. I. Requirement for the host-cell nucleus. J. Virol. 29:705-715.
14. Kane, E. M., and S. Shuman. 1993. Vaccinia virus morphogenesis is blocked by a temperature-sensitive mutation in the I7 gene that encodes a virion component. J. Virol. 67:2689-2698.
15. Kern, E. R. 2003. In vitro activity of potential anti-poxvirus agents. Antivir. Res. 57:35-40.
16. Lalezari, J. P., and B. D. Kuppermann. 1997. Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14(Suppl. 1):S27-S31.
17. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A.-M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M.-A. Poupart, J. Rancourt, R. E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C.-L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
18. Li, S. J., and M. Hochstrasser. 1999. A new protease required for cell-cycle progression in yeast. Nature 398:246-251.
19. Miravalle, A., and K. L. Roos. 2003. Encephalitis complicating smallpox vaccination. Arch. Neurol. 60:925-928.
20. Moss, B., E. N. Rosenblum, E. Katz, and P. M. Grimley. 1969. Rifampicin: a specific inhibitor of vaccinia virus assembly. Nature 224:1280-1284.
21. Raczynski, P., and R. C. Condit. 1983. Specific inhibition of vaccinia virus growth by 2′-O-methyladenosine: isolation of a drug-resistant virus mutant. Virology 128:458-462.
22. Rosenkranz, H. S., H. M. Rose, C. Morgan, and K. C. Hsu. 1966. The effect of hydroxyurea on virus development II. Vaccinia virus. Virology 28:510-519.
23. Spurr, A. R. 1969. A low-viscosity epoxy resin embedding medium for electron microscopy. J. Ultrastruct. Res. 26:31-43.
24. VanSlyke, J. K., and D. E. Hruby. 1994. Immunolocalization of vaccinia virus structural proteins during virion formation. Virology 198:624-635.
25. Venable, J. H., and R. Coggeshall. 1965. A simplified lead citrate stain for use in electron microscopy. J. Cell Biol. 25:407-408.